Surfacide recently launched its Helios+ UV-C System, the first whole room microbial reduction device to receive a 510(k) clearance from the U.S. Food and Drug Administration (FDA). Helios+ sets a new standard by utilizing 3 emitters in a single cycle to achieve whole room microbial reduction against multi-drug-resistant organisms, including Clostridioides difficile (C. diff) spores. This patented multiple emitter system requires no repositioning in a patient or operating rooms, delivering speed, efficacy, and adaptability to healthcare facilities worldwide.
Surfacide Helios+ is the only whole room microbial reduction device using continuous 254 nm germicidal UV light with FDA clearance to be marketed and distributed in the United States. Helios+ is intended for use in unoccupied operating rooms, hospital rooms and other clinical settings where non-critical medical devices are present, as an adjunct to existing manual cleaning and disinfection practices.
The Helios+ UV-C System harnesses Surfacide’s patented Power of Three technology, which utilizes up to three emitters in a single cycle, eliminating the need for repositioning and maximizing workflow. This innovative design ensures comprehensive coverage, reduces shadows and delivers UV-C energy to high-touch surfaces, while considering the complex challenges presented by both vertical and horizontal orientations. Validated to achieve whole room microbial reduction, Helios+ delivers a defined dose to a defined distance and area, ensuring dependable microbial reduction in clinical environments.
Designed with versatility in mind, Helios+ adapts to a wide range of settings, offering customizable configurations for:
- Patient Rooms
- Patient Bathrooms
- Intensive Care Units (ICUs)
- Procedure Rooms (Operating Rooms, Cath Labs, L&D, Endoscopy Suites)
With no repositioning necessary, Helios+ optimizes staff productivity and minimizes downtime, making it an ideal solution for high-traffic, high-risk environments. Helios+ also introduces LTE connectivity in addition to Wi-Fi as a standard feature, which can offer significant benefits to the user including enhanced reliability, ease of use, and connectivity to the cloud.
Simultaneous use of multiple UV-C emitters can reduce shadowed areas by providing multiple direct lines of sight to non-critical medical device surfaces. Helios+ features a parabolic concentrator that uses reflectors to harness and direct energy from all its lamps in one direction, covering vertical and horizontal surfaces and ensuring consistent microbial reduction.
The Helios+ UV-C system includes 3 UV-C emitters, 3 safety sensors, a control tablet, and 2 joiners that link the emitters for transport and also serve as warning signage when the device is in use.
Helios+ went through rigorous performance testing to ensure it meets the FDA’s Special Controls, including:
- Microbial Reduction Testing
- Safety Testing
- Biocompatibility Testing
- Software and Cyber Security Testing
“Helios+ represents an immense leap forward in infection prevention,” said Gunner Lyslo, founder and CEO of Surfacide. “As the only FDA-authorized triple emitter system to deliver whole room microbial reduction without the need to reposition devices, Helios+ empowers healthcare facilities to create safer environments for patients and staff with remarkable speed and reliability.”
